This week’s headlines include: Medigene gets OK for first trial of T-cell receptor therapy, Mesoblast stem Cell Therapy meets goal of pediatric Graft vs. Host study, Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict, U.S. health officials reverse stance on AstraZeneca’s flu vaccine, and In mice, a single vaccine prompts the immune system to fight breast, lung and skin cancers.
In Case You Missed It, Recent Articles on Cell Culture Dish and Downstream Column:
pH is one of the most important parameters in maintaining a healthy cell culture. This week’s Two Minute Tuesday educational video is the first of a three part series of interviews with Dr. Robert Garrahy, Vice President of Bioprocess Technologies at Broadley-James Corporation. Dr. Garrahy is interviewed about the most important selection factors in pH probes, as well as important cleaning and maintenance recommendations…Cancer Research.” During this Ask the Expert session, we covered topics related to innovative tools and methods in cancer research. One of the topics explored was the use of spheroids and organoids and enabling technologies for cancer research. There were also several discussions around the culture of various cancer cell types, including medium and extracellular matrices choices. There was a very interesting question about new tools that are in development to aid in cancer research…
Corning® Nu-Serum™ I/IV Growth Medium Supplements for Reduced-serum Conditions with Fibroblast/Kidney Epithelial CellsWith the movement towards reduced-serum and serum-free conditions for cell culture, defined formulations and low-protein alternatives are of increasing value. Fetal bovine serum (FBS) is traditionally used as a supplement in media for cell and tissue culture at final concentrations of 5% to 10%. However, it can introduce risk as FBS lot-to-lot variation may negatively impact cellular and molecular studies, and can introduce artifacts due to the presence of unknown compounds, proteins, growth factors, and other undefined components1. Additionally, the high protein content of serum can introduce complications with protein purification. Corning® Nu-Serum™ growth medium supplements provide more cost-effective, low protein alternatives that can be utilized as a 1:1 direct replacement for FBS in cell culture media…
Utilizing a Protein A Resin Platform Approach for Purification of Antibody Fragments and Single Domain Antibodies Reduces Process TimeFollowing the wave of successful commercial monoclonal antibody products, various forms of antibody fragments are now becoming an important class of next-generation therapeutic proteins. This includes Fabs and fusion proteins of the Fab variable domains. From the variable domain of the heavy-chain antibodies of camelids, the VHH sdAbs have been derived. These VHHs represent some of the smallest antigen binding antibody-derived proteins. As such they are more stable than full size mAbs, can be produced in microbial organisms, and offer higher target binding events per gram of product. Due to the lack of an Fc region, these antibody fragments cannot be captured with most engineered Protein A affinity ligands. However, Amsphere™ A3 Protein A ligand exhibits a high affinity for VHH single domain antibodies… podcast and accompanying article, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the evolution of Protein A including the latest developments in Protein A chromatography resins. We also discussed what the future holds for this purification mainstay and how it can continue to address the changing needs of biopharma…
Webinars:With over 40 years combined experience, Purolite Life Sciences’ Global Applications Director (Agarose), Hans Johansson and eXmoor Pharma Bioprocess Engineer, Dr David Vincent will present a case study that looks at the purification performance of different base matrices, and protein A ligands to support the concept of dual sourcing. The webinar will also discuss some of the production challenges that may face the Cell and Gene Therapy industry, as an increasing number of products are scaled up and out.
Podcasts:Check out our podcast channel. We have 15 great podcasts covering drug discovery, stem cell culture, upstream and downstream biomanufacturing and more! Click below to download through iTunes or Google play:
“Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem Cell Therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday. The study tested Mesoblast’s off-the-shelf stem cell product, remestemcel-L, in 55 children who did not respond to steroids after a bone marrow transplant triggered acute Graft Versus Host Disease (aGVHD)…”